Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2010, Article ID 131895, 8 pages
http://dx.doi.org/10.1155/2010/131895
Research Article

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells

1Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium
2Le Departement d'Hématologie Clinique, Centre Hospitalier Universitaire de Liège, 4000 Liège, Belgium
3Mundipharma International Limited, Milton Road, Cambridge CB4 0GW, UK

Received 1 July 2010; Accepted 6 September 2010

Academic Editor: Estella M. Matutes

Copyright © 2010 Liesbeth Bieghs et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Caers, I. Vande Broek, H. De Raeve et al., “Multiple myeloma—an update on diagnosis and treatment,” European Journal of Haematology, vol. 81, no. 5, pp. 329–343, 2008. View at Publisher · View at Google Scholar · View at PubMed
  2. C. M. Galmarini, F. Popowycz, and B. Joseph, “Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy,” Current Medicinal Chemistry, vol. 15, no. 11, pp. 1072–1082, 2008. View at Publisher · View at Google Scholar
  3. G. A. Kicska, L. Long, H. Hörig et al., “Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 8, pp. 4593–4598, 2001. View at Publisher · View at Google Scholar · View at PubMed
  4. S. Bantia, P. J. Miller, C. D. Parker et al., “Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)—a novel potent and orally active immunosuppressive agent,” International Immunopharmacology, vol. 1, no. 6, pp. 1199–1210, 2001. View at Publisher · View at Google Scholar
  5. S. Bantia, S. L. Ananth, C. D. Parker, L. L. Horn, and R. Upshaw, “Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor—BCX-1777,” International Immunopharmacology, vol. 3, no. 6, pp. 879–887, 2003. View at Publisher · View at Google Scholar · View at PubMed
  6. K. Balakrishnan, R. Nimmanapalli, F. Ravandi, M. J. Keating, and V. Gandhi, “Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells,” Blood, vol. 108, no. 7, pp. 2392–2398, 2006. View at Publisher · View at Google Scholar · View at PubMed
  7. R. Alonso, M. López-Guerra, R. Upshaw et al., “Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM,” Blood, vol. 114, no. 8, pp. 1563–1575, 2009. View at Publisher · View at Google Scholar · View at PubMed
  8. J. Kuroda and M. Taniwaki, “Involvement of BH3-only proteins in hematologic malignancies,” Critical Reviews in Oncology/Hematology, vol. 71, no. 2, pp. 89–101, 2009. View at Publisher · View at Google Scholar · View at PubMed
  9. I. Homminga, C. M. Zwaan, C. Y. Manz et al., “In-vitro efficacy of the deoxyguanoside analogs forodesine (BCX-1777) and ARA-G in pediatric acute lymphoblastic leukemia,” ASH Annual Meeting Abstracts, vol. 114, no. 22, p. 2038, 2009. View at Google Scholar
  10. M. Duvic, A. Forero-Torres, F. Foss et al., “Oral forodesine (Bcx-1777) is clinically active in refractory cutaneous T-cell lymphoma: results of a phase I/II study,” Blood, vol. 108, no. 11, p. 698a, 2006. View at Google Scholar
  11. M. Duvic, F. Foss, E. Olsen et al., “Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma,” Blood, vol. 104, no. 11, p. 683a, 2004. View at Google Scholar
  12. R. R. Furman, W. Gandhi, J. C. Bennett et al., “Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in phase I/II studies in patients with B-cell acute lymphoblastic leukemia,” Blood, vol. 104, no. 11, p. 750a, 2004. View at Google Scholar
  13. R. R. Furman, G. Iosava, L. Isola et al., “Forodesine (FodosineTM), a PNP inhibitor active in relapsed or refractory T-cell leukemia patients—(phase II study),” Blood, vol. 106, no. 11, p. 259a, 2005. View at Google Scholar
  14. V. Gandhi, J. M. Kilpatrick, W. Plunkett et al., “A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine),” Blood, vol. 106, no. 13, pp. 4253–4260, 2005. View at Publisher · View at Google Scholar · View at PubMed
  15. T. Robak, A. Korycka, L.-M. Ewa, and P. Robak, “Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases,” Molecules, vol. 14, no. 3, pp. 1183–1226, 2009. View at Publisher · View at Google Scholar · View at PubMed
  16. T. Robak, A. Korycka, M. Kasznicki, A. Wrzesien-Kus, and P. Smolewski, “Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications,” Current Cancer Drug Targets, vol. 5, no. 6, pp. 421–444, 2005. View at Publisher · View at Google Scholar
  17. E. H. Kraut, J. J. Crowley, M. R. Grever et al., “Phase II study of fludarabine phosphate in multiple myeloma. A Southwest oncology group study,” Investigational New Drugs, vol. 8, no. 2, pp. 199–200, 1990. View at Google Scholar
  18. M. A. Dimopoulos, H. M. Kantarjian, E. H. Estey, and R. Alexanian, “2-Chlorodeoxyadenosine in the treatment of multiple myeloma,” Blood, vol. 80, no. 6, p. 1626, 1992. View at Google Scholar
  19. B. Björkstrand, T. Rasmussen, K. Remes, A. Gruber, T.-T. Pelliniemi, and H. E. Johnsen, “Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study,” European Journal of Haematology, vol. 70, no. 6, pp. 379–383, 2003. View at Publisher · View at Google Scholar
  20. K. Asosingh, J. Radl, I. Van Riet, B. Van Camp, and K. Vanderkerken, “The 5TMM series: a useful in vivo mouse model of human multiple myeloma,” Hematology Journal, vol. 1, no. 5, pp. 351–356, 2000. View at Google Scholar
  21. K. Asosingh, H. De Raeve, P. Croucher et al., “In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells,” Experimental Hematology, vol. 29, no. 1, pp. 77–84, 2001. View at Publisher · View at Google Scholar
  22. J. W. Pickering and F. B. Gelder, “A human myeloma cell line that does not express immunoglobulin but yields a high frequency of antibody-secreting hybridomas,” Journal of Immunology, vol. 129, no. 1, pp. 406–412, 1982. View at Google Scholar
  23. B. I. S. Srivastava and J. Minowada, “Terminal deoxynucleotidyl transferase activity in a cell line (Molt-4) derived from the peripheral blood of a patient with acute lymphoblastic leukemia,” Biochemical and Biophysical Research Communications, vol. 51, no. 3, pp. 529–535, 1973. View at Google Scholar
  24. E. Menu, J. Garcia, X. Huang et al., “A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model,” Cancer Research, vol. 68, no. 14, pp. 5519–5523, 2008. View at Publisher · View at Google Scholar · View at PubMed
  25. E. Menu, E. V. Valckenborgh, B. V. Camp, and K. Vanderkerken, “The role of the insulin-like growth factor 1 receptor axis in multiple myeloma,” Archives of Physiology and Biochemistry, vol. 115, no. 2, pp. 49–57, 2009. View at Publisher · View at Google Scholar · View at PubMed
  26. S. Chen-Kiang, “Cell-cycle control of plasma cell differentiation and tumorigenesis,” Immunological Reviews, vol. 194, pp. 39–47, 2003. View at Publisher · View at Google Scholar
  27. M. Jourdan, T. Reme, H. Goldschmidt et al., “Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells,” British Journal of Haematology, vol. 145, no. 1, pp. 45–58, 2009. View at Publisher · View at Google Scholar · View at PubMed
  28. M. Huang, Y. Wang, J. Gu et al., “Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H,” Leukemia Research, vol. 32, no. 8, pp. 1268–1278, 2008. View at Publisher · View at Google Scholar · View at PubMed